Ajanta Pharma’s robust growth and profitability stem from strategic initiatives, including reducing raw material costs, enhancing production capabilities with new facilities, and aggressive debt reduction.
The low tax rate (~15-16% in FY10) likely results from incentives or tax holidays.
The high debt was initially concerning but is now under control, with the debt-to-equity ratio down to 0.93.
The impressive 1HFY11 performance is due to a combination of factors: efficient debt management lowering interest costs, the new API facility reducing raw material expenses, and overall operational efficiencies.
These improvements suggest sustainable growth and profitability moving forward.
Taknikinc is an engineering Consultant which provide engineering consultancy services to chemical, pharmaceutical, industries, Water treatment plant provider, trade industrial chemicals, for order kindly contact -9510430147 or email us- inquiry@taknikinc.com.
| Subscribe To Our Free Newsletter |
